Necessary cookies make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. These cookies cannot be switched off in Tann Westlake’s systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences or logging in or completing forms. You may be able to decline these cookies through your own web browser, but then necessary parts of the website will not work. These cookies do not store any personally identifiable information or other information that Tann Westlake could use to identify you.

Cookie	Expiry	Domain	Company
Cookie CookieConsent	Expiry Session	Domain https://elegantstudy.com/	Company Tann Westlake
Stores your cookie consent session for our site. It contains no information other than whether you have opted in or out for each cookie level.
Cookie pll_language	Expiry Session	Domain https://elegantstudy.com/	Company Polylang
Polyang uses a cookie: This cookie is used to determine the preferred language of the visitor and set the language accordingly on the website if or when they visit again.
Cookie wordpress_test_cookie	Expiry Session	Domain https://elegantstudy.com/	Company Wordpress
WordPress also sets wordpress_test_cookie cookie to check if the cookies are enabled on the browser to provide appropriate user experience to the users. This cookie is used on the front-end, even if you are not logged in.
Cookie prescreener-click-tracking	Expiry Session	Domain https://elegantstudy.com/	Company Tann Westlake
The prescreener-click-tracking cookie stores the Fathom tracking code, specific to the clinic you are on, to allow for clinic-specific event tracking when completing the pre-screener form. This allows for your pre-screener form submission to be sent to the correct clinic.

Early-stage breast cancer with high risk of recurrence

The ELEGANT study is a clinical trial that compares a potential new treatment called elacestrant to standard-of-care endocrine therapy in node-positive early-stage breast cancer with a high risk of recurrence.

For patients and caregivers

Explore if you or your loved one is eligible to participate in the ELEGANT Study.

Learn how to take part

For healthcare providers

Learn more about elacestrant as a potential treatment regimen in early-stage breast cancer.

Explore the study

The ELEGANT study is a clinical trial designed to evaluate a potential new treatment for early-stage breast cancer with a high risk of recurrence.

Connect with the nearest study site for more information.

Find a study center

Cookies

Early-stage breast cancer with high risk of recurrence

For patients and caregivers

For healthcare providers

The ELEGANT study is a clinical trial designed to evaluate a potential new treatment for early-stage breast cancer with a high risk of recurrence.

The ELEGANT study is a clinical trial designed to evaluate a potential new treatment for early-stage breast cancer with a high risk of recurrence.